Newcastle Preclinical In Vivo Imaging Facility



The following publications resulted from research projects which acknowledge the use of the In Vivo Imaging System facility.


Luli S, Di Paolo D, Perri P, Brignole C, Hill SJ, Brown H, et al. A new fluorescence-based optical imaging method to non-invasively monitor hepatic myofibroblasts in vivo. J Hepatol. 2016. Epub 2016/04/14. doi: 10.1016/j.jhep.2016.03.021. IF 11.336

Pal D, Blair HJ, Elder A, Dormon K, Rennie KJ, Coleman DJ, et al. Long-term in vitro maintenance of clonal abundance and leukaemia-initiating potential in acute lymphoblastic leukaemia. Leukemia. 2016. PubMed PMID: 27109511. IF 10.431

Fox C, Cocchiaro P, Oakley F, Howarth R, Callaghan K, Leslie J, et al. Inhibition of lysosomal protease cathepsin D reduces renal fibrosis in murine chronic kidney disease. Sci Rep. 2016;6:20101. PubMed PMID: 26831567; IF 5.578

Roughan JV, Bertrand HG, Isles HM. Meloxicam prevents COX-2-mediated post-surgical inflammation but not pain following laparotomy in mice. Eur J Pain. 2016;20(2):231-40. PubMed PMID: 25908253. IF 3.218

Moles A, Butterworth JA, Sanchez A, Hunter JE, Leslie J, Sellier H, et al. A RelA(p65) Thr505 phospho-site mutation reveals an important mechanism regulating NF-kappaB-dependent liver regeneration and cancer. Oncogene 2016. PubMed PMID: 26853469. IF 8.459

Miller, A., Burson, H., Söling, A. and Roughan, J. V. Welfare assessment following heterotopic or orthotopic inoculation of bladder cancer in C57BL/6. PLOS ONE 2016. Submitted. IF 3.234


Wilson CL, Jurk D, Fullard N, Banks P, Page A, Luli S, et al. NFkappaB1 is a suppressor of neutrophil-driven hepatocellular carcinoma. Nat Commun. 2015;6:6818. PubMed PMID: 25879839. IF 11.47

Hunter JE, Butterworth JA, Zhao B, Sellier H, Campbell KJ, Thomas HD, et al. The NF-kappaB subunit c-Rel regulates Bach2 tumour suppressor expression in B-cell lymphoma. Oncogene. 2015. PubMed PMID: 26522720. IF 8.459


Scherr M, Elder A, Battmer K, Barzan D, Bomken S, Ricke-Hoch M, et al. Differential expression of miR-17~92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia. Leukemia. 2014;28(3):554-65. PubMed PMID: 24280866. IF 10.431

Vormoor B, Knizia HK, Batey MA, Almeida GS, Wilson I, Dildey P, et al. Development of a preclinical orthotopic xenograft model of ewing sarcoma and other human malignant bone disease using advanced in vivo imaging.PLoS One. 2014;9(1):e85128. PubMed PMID: 24409320. IF 3.234


Moles A, Sanchez AM, Banks PS, Murphy LB, Luli S, Borthwick L, et al. Inhibition of RelA-Ser536 phosphorylation by a competing peptide reduces mouse liver fibrosis without blocking the innate immune response. Hepatology. 2013;57(2):817-28. PubMed PMID: 22996371. IF 11.055

Bomken S, Buechler L, Rehe K, Ponthan F, Elder A, Blair H, et al. Lentiviral marking of patient-derived acute lymphoblastic leukaemic cells allows in vivo tracking of disease progression. Leukemia. 2013;27(3):718-21. PubMed PMID: 22858908. IF 10.431

Robinson SM, Mann DA, Manas DM, Oakley F, Mann J, White SA. The potential contribution of tumour-related factors to the development of FOLFOX-induced sinusoidal obstruction syndrome. Br J Cancer. 2013;109(9):2396-403. PubMed PMID: 24113143. IF 4.836